Slide 1: Precision dermatology powered by synthetic biology
CORPORATE PRESENTATION August 2026 Precision dermatology powered by synthetic biology.
Slide 2: Disclaimer and Special Note Regarding Forward-Looking Statements
DISCLAIMER AND SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document has been prepared and is made for informational purposes only to familiarize yourself with Azitra, Inc. (“Azitra”, the “Company,” “we,” “us,” and “our”). This document is neither an offer to sell or purchase, nor a solici
Slide 3: Three foundational platforms for precision dermatology
Three foundational platforms for precision dermatology PO WERED BY SYNTHETIC BIOLOG Y A ND TH E META GENOM E Bacterial Cell Library • Proprietary, robust library of ~1,500 microbial strains • Engineered and non-engineered bacterial chasses • Over 60 species in house, mostly Staphylococcus epidermidi
Slide 4: Azitra's pipeline
Azitra’s pipeline Cosmeceutical ingredients RES EARCH HUM AN T EST ING C O M ME R C I A L I Z A T I O N ATR-COSF: filaggrin protein ingredient FDA-regulated candidates for drug development DIS COVER Y IND -EN ABLI NG PH ASE 1 PH ASE 2 PH ASE 3 COMMERCI AL ATR-01 Filaggrin-secreting S. epidermidis Ic
Slide 5: ATR-COSF Program: Recombinant filaggrin protein
ATR-COSF Program Recombinant filaggrin protein
Slide 6: ATR-COSF: topical filaggrin + bacterial lysate for cosmeceutical indications
ATR-COSF: topical filaggrin + bacterial lysate for cosmeceutical indications Insert gene fragment that Insert filaggrin gene into Isolate supernatant of filaggrin- encodes filaggrin chromosome of S. epidermidis producing S. epidermidis Azitra plasmid S. epidermidis Filaggrin-producing S. epidermidis
Slide 7: Filaggrin's function in the skin
Filaggrin’s function in the skin ✓ Breaks down into small products that attract and retain water in the skin ✓ Byproducts help acidify the skin ✓ Plays a crucial role in skin barrier formation, reducing water loss and preventing moisture escape ✓ Reinforced skin barrier helps protect against environ
Slide 8: ATR-COSF delivers filaggrin below the stratum corneum after single dose
ATR-COSF delivers filaggrin below the stratum corneum after single dose Application of ATR-COSF on skin with reduced filaggrin levels Untreated Skin with Normal levels Skin model with Reduced 8 hr post application Field 24 hr post 5 application filaggrin levels rhFlg 9-10 SC SG SC KH SG DNA SC = Str
Slide 9: Human skin elasticity measurement vs supernatant concentration
Human skin elasticity measurement vs supernatant concentration Abdominal skin explant model • Hydrogels containing 0.3% (by weight) of active ingredient • Restored ex vivo abdominoplasty skin elasticity to values observed in belly Placebo Treated Active Treated - 0.3% Supernatant skin of a healthy s
Slide 10: ATR-04 Program: EGFR inhibitor-associated rash
ATR-04 Program EGFR inhibitor-associated rash
Slide 11: ATR-04: auxotrophic S. epidermidis for EGFR inhibitor-associated rash
ATR-04: auxotrophic S. epidermidis for EGFR inhibitor-associated rash ATR-04 Summary ATR-04 Key Facts • Chemotherapy agents such as EGFR inhibitors and immunotherapies such as Primary Mechanism: early BTK inhibitors lead to an aggressive and debilitating rash on most patients Topical IL36𝛄…
Slide 12: EGFRi-driven rash is highly prevalent with significant clinical impact
EGFRi-driven rash is highly prevalent with significant clinical impact Grade 1 Grade 2 Grade 3 Grade 4 • Rash severity often linked to cancer drug dosing and correlates with S. aureus levels on the skin • Rash can lead to significant changes in course of therapy and QOL • As many as 15-20% discontin
Slide 13: Mechanism of action of ATR-04
Mechanism of action of ATR-04 Potential decreases in IL-36𝛄 cytokine signaling Inhibits S. aureus growth and biofilm Collectively, ATR-04 addresses rash severity driven by EGFR inhibition Expected to lead to decreased inflammation 13
Slide 14: In vitro data show ATR-04 reduces erlotinib-induced IL-36γ and S. aureus
In vitro data show ATR-04 reduces erlotinib-induced IL-36𝛄 and S. aureus IL-36𝛄 reduction in reconstructed human epidermis S. aureus reduction on ex vivo pig skin -99% -75% Untreated Erlotinib Erlotinib + 10 7 Erlotinib + 108 SA USA300 SA USA300 + SE484 + SE484 + SE484 CFU ATR-04 CFU ATR-04 0…
Slide 15: Phase 1/2 clinical trial design: IND cleared August 2024
Phase 1/2 clinical trial design: IND cleared August 2024 Study overview Design Cohort 1: Single dose to multiple Cohort 2: Multiple dosing • Multicenter, randomized, double-blind, dosing vehicle-controlled study in adults (n=32) with EGFRi associated dermal toxicity 3:1 randomization 3:1 randomizati
Slide 16: Future Directions
Future Directions
Slide 17: SyMPL technology: stealth by engineering - the problem
SyMPL (SyngenicDNA minicircle plasmid) technology: stealth by engineering The problem Current biomanufacturing processes are unable to overcome bacterial defenses, leading to high costs/inefficiency Current challenges in genetic engineering: • 99% of bacteria are genetically 'Intractable' due to def
Slide 18: SyMPL technology: stealth by engineering - the solution
SyMPL (SyngenicDNA minicircle plasmid) technology: stealth by engineering The solution SyMPL technology to evade bacterial defenses for improved genetic engineering Traditional engineering SyMPL engineering The solution: • Instead of adding a disguise to the human DNA, remove specific recognition mo
Slide 19: SyMPL applications: begin with proven markets
SyMPL applications: begin with proven markets Initial Product Pipeline of Multiple ~$1B+ Opportunities: Bio-Identical Filaggrin The Issue: Unstable gene prevents production The Solution: Minicircle stabilization enables mass production mRNA Kit The Issue: T7 Pol is toxic; DNA is unstable The Solutio
Slide 20: ATR-COSF and ATR-04 anticipated milestones in 2026
ATR-COSF and ATR-04 bring value-creating anticipated milestones in 20261 2026 Expected upcoming Q1 Q2 Q3 Q4 milestones:1 Filaggrin pipeline First-in-human wrinkle Proof-of-concept preclinical studies study • Q4: first-in-human ATR-COSF Repeat dose study results Clinical results ex vivo skin model •
Slide 21: Thank you
THANK YOU Precision dermatology powered by synthetic biology.
Slide 22: Appendix
APPENDIX
Slide 23: Azitra is led by world-class management team
Azitra is led by world-class management team • Prior Co-Founder and VP of Operations at Acerta Pharma – Sold for $6.3 billion Francisco Salva, MSc. President and CEO • Formerly Senior Director –Corporate Development at Pharmacyclics • 25+ years experience in life science venture capital, investment
Slide 24: Using synthetic biology and S. epidermidis biology for skin therapeutics
Using synthetic biology and S. epidermidis biology for skin therapeutics Identify human or bacterial Engineer auxotrophy to Colonize affected skin with Secrete active molecule throughout layers 1 protein or molecule of interest 2 control strain growth 3 engineered strain 4 of the epidermis for thera
Slide 25: ATR-01 Program: Ichthyosis vulgaris
ATR-01 Program Ichthyosis vulgaris
Slide 26: ATR-01: topical filaggrin delivery for ichthyosis vulgaris
ATR-01: topical filaggrin delivery for ichthyosis vulgaris ATR-01 Summary ATR-01 Key Facts • Ichthyosis vulgaris is a common autosomal dominant disease with no current FDA-approved treatment option Primary Mechanism: Topical protein replacement • Characterized by dry, rough, and scaly skin o Caused
Slide 27: Mechanism of action of ATR01-616
Mechanism of action of ATR01-616 27
Slide 28: Dose-dependent filaggrin delivery in ex vivo pig skin with ATR01-616
Dose-dependent filaggrin delivery in ex vivo pig skin with ATR01-616 ✓ ATR01-616 delivers filaggrin in a dose-dependent manner on ex vivo pig skin ✓ No human filaggrin detected in pig skin using vehicle 28
Slide 29: ATR-01 (SE616) decreases transepidermal water loss on ex vivo damaged skin
ATR-01 (SE616) decreases transepidermal water loss (TEWL) on ex vivo damaged skin Ex vivo model Change in TEWL over time Total change in TEWL 29
Slide 30: ATR-01 summary
ATR-01 summary ✓ ATR01-616 delivers human filaggrin in a dose-dependent manner, and delivers filaggrin to the stratum granulosum in human skin ✓ Filaggrin delivered from ATR01-616 is functional, measured by keratin collapse assays and shown to colocalize with keratin in fluorescent imaging ✓ ATR01-6